재발성/불응성 급성 골수성 백혈병 환자를 대상으로 BL-M11D1의 안전성, 내약성, 약동학 프로파일 및 예비 효능을 평가하기 위한 다기관, 공개 라벨 제1상 임상 연구
재발성/불응성 급성 골수성 백혈병 환자를 대상으로 BL-M11D1의 안전성, 내약성, 약동학 프로파일 및 예비 효능을 평가하기 위한 다기관, 공개 라벨 제1상 임상 연구.
The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
BL-M11D1-HM-101 is a multi-center, Phase 1 study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.
This study will be conducted in two parts (dose escalation, and dose finding). Cohort A will be dosed on Days 1, 8,15 of a continuous 28-day treatment cycle. The cohort has different dose groups. Cohort B will be dosed on Days 1, 4, 7 or 8 of a continuous 28-day treatment cycle. The cohorts have different dose groups.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 1단계
연락처 및 위치
연구 장소
-
-
California
-
Duarte, California, 미국, 91010
- City of Hope
-
Los Angeles, California, 미국, 90095
- UCLA Ronald Reagan Medical Center
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- University of Colorado Anschutz Medical Campus
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06511
- Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven
-
-
Florida
-
Tampa, Florida, 미국, 33612
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- Northwestern Memorial Hospital
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Michigan
-
Grand Rapids, Michigan, 미국, 49546
- START Midwest/The Cancer and Hematology Center
-
-
New Jersey
-
Hackensack, New Jersey, 미국, 07601
- John Theurer Cancer Center-Hackensack
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45236
- Oncology Hematology Care Clinical Trials, LLC
-
Columbus, Ohio, 미국, 43210
- The Ohio State University Comprehensive Cancer Center
-
-
Oregon
-
Eugene, Oregon, 미국, 24224
- WVCI Oncology Associates of Oregon
-
Portland, Oregon, 미국, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19111
- Temple Health Fox Chase Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- SCRI -TriStar BMT
-
-
Texas
-
Houston, Texas, 미국, 77030
- MD Anderson Cancer Center
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- Virginia Cancer Specialists
-
-
Washington
-
Seattle, Washington, 미국, 98109
- Fred Hutchinson Cancer Center
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Signed the informed consent
- Age ≥18 years
- Has a life expectancy of ≥3 months
- Relapsed and/or refractory CD33-positive AML as determined by local pathology review that has failed initial standard of care therapy. Diagnosis of primary AML or AML secondary to myelodysplastic syndromes. Relapsed or refractory status. CD33-positive as confirmed by local flow cytometry or cytology
- Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2
- Toxicity of previous anticancer therapy has returned to Grade ≤1 as defined by NCI CTCAE V5.0, except for alopecia and endocrinopathies controlled by replacement therapy that must be Grade ≤2
- Has adequate liver and renal function before registration, defined as: a. Hepatic function: Total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for subjects with Gilbert's syndrome), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN b. Renal function: Creatinine clearance ≥50 mL/min (Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration [CKD-Epi], or Modification of Diet in Renal Disease Study [MDRD] equations)
- Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and for 7 months after the last dose of study treatment. An additional contraceptive method, such as a barrier method (eg, condom), is recommended
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and must be nonlactating
Exclusion Criteria:
-
Subjects with acute promyelocytic leukemia (APL) or chronic myelogenous leukemia in blast crisis (CML)
-
Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other anticancer therapy within 2 weeks) prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration, or palliative radiotherapy within 2 weeks prior to the first administration
-
Subjects with history of severe heart disease, such as symptomatic congestive heart failure (CHF) ≥ Grade 2 (CTCAE 5.0), New York Heart Association (NYHA) ≥ Grade 2 heart failure, history of transmural myocardial infarction, unstable cardiac arrhythmias or angina pectoris within 6 months before screening
-
Subjects with prolonged QT interval (QTcF >470 msec), complete left bundle branch block, Grade 3 atrioventricular block or a history of additional risk factors for Torsades de Pointes (TdP; eg, heart failure as defined in Exclusion Criterion 3, chronic or recurrent hypokalemia that requires medical intervention, congenital long QT syndrome, family history of long QT syndrome) or any current concomitant medication known to prolong the QT/QTc interval or cause TdP
-
Active autoimmune diseases and inflammatory diseases, such as: systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, etc., except for Type I diabetes, hypothyroidism that can be controlled only by standard of care treatment, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis)
-
Subjects with other prior or concurrent malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with as disease-free interval of at least 1 year
-
Subjects with poorly controlled hypertension or uncontrolled hypertension by two or more antihypertensive drugs (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg)
-
Subjects with active acute or chronic graft vs. host disease (aGVHD or cGVHD) should be excluded from this study. Subjects with GVHD who are receiving treatment with systemic glucocorticoids >10 mg/day equivalent of prednisone should also be excluded from the study; however, treatment with low-dose glucocorticoids (≤10 mg/day equivalent of prednisone) is permitted
-
Subjects currently receiving immunosuppressive therapy should be excluded from this study.
-
Clinical evidence of disseminated intravascular coagulation (DIC). Smoldering low grade DIC is allowed after discussion with the sponsor
-
Subjects with stroke or transient ischemic attack (TIA) within 6 months before screening
-
Subjects with a thromboembolic event (eg, deep vein thrombosis [DVT] or pulmonary embolism [PE]) within 6 months before screening except for those who are clinically stable and receiving treatment with adequate anticoagulant therapy for at least 3 weeks before screening
-
Subjects with active central nervous system (CNS) AML will be excluded. A lumbar puncture does not need to be performed unless there is clinical suspicion of CNS involvement per investigator judgment. Concurrent therapy for CNS prophylaxis or continuation of therapy for controlled CNS AML is allowed with the approval of the sponsor
-
Subjects with pre-existing ≥Grade 2 peripheral neuropathy
-
Subjects with advanced/ clinically significant lung diseases, such as poorly controlled COPD and asthma, restrictive lung disease, pulmonary hypertension etc.
-
Subjects who have a history of noninfectious interstitial lung disease (ILD)/ pneumonitis that required treatment with steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
-
Subjects who have a history of anaphylaxis or severe hypersensitivity to recombinant humanized antibodies or human-mouse chimeric antibodies or any of the components of BL-M11D1
-
Subjects with known human immunodeficiency virus infection (HIV Ab positive) Subjects are allowed to participate if all of the following criteria are met: (1) Undetectable HIV RNA and CD4 count ≥350 cells/μL at screening, (2) No AIDS defining opportunistic infection within 12 months prior to screening, (3) On stable antiretroviral therapy (ART) for at least 4 weeks prior to screening with projected continuation of ART as clinically indicated while on the study
-
Subjects with active Hepatitis B virus (HBV) infection (positive HBsAg test). Subjects with chronic inactive HBV infection are eligible if they meet all of the following criteria:
- Have a HBV DNA viral load ≤ 500 IU/mL
- Have normal AST and ALT, OR if liver involvement is present, has AST and ALT <3 × ULN which are not attributed to HBV infection
- on antiviral treatment, as clinically indicated
-
Subjects with active Hepatitis C virus (HCV) infection (HCV antibody positive and HCV-RNA > the lower limit of detection). Subjects with a positive anti-HCV antibody are eligible only if PCR is negative for HCV RNA
-
Subjects with active or latent tuberculosis
-
Subjects with active and uncontrolled infections requiring IV antibiotic, antiviral, or antifungal treatment, such as severe pneumonia, bacteremia, sepsis, etc., within 1 week prior to first dose of study treatment. Subjects on stable oral antimicrobials with no clinical or laboratory evidence of active infection are eligible
-
Received an investigational drug within 2 weeks prior to first dose of study treatment.
-
Subjects who are pregnant, breastfeeding, or planning to become pregnant during the study
-
Prior treatment with a topoisomerase inhibitor-based antibody-drug conjugate (ADC.)
-
Previous history of significant gastrointestinal conditions, including Grade 3 or higher diarrhea, colitis, gastrointestinal bleeding and history of major gastrointestinal surgeries
28. Progressed on more than 2 different lines of systemic cytotoxic therapies; patients with 3 prior lines of systemic cytotoxic therapy or with prior allogeneic stem cell transplant may be enrolled upon consultation and approval from the sponsor
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Experimental: Cohort A BL-M11D1 administered Days 1, 8 and 15 in 28-day cycle
Cohort A: BL-M11D1 will be administered on Days 1, 8 and 15 by intravenous infusion every 28 days. |
The study includes 2 parts: Part 1 Dose escalation and Dose Finding |
|
실험적: Experimental: Cohort B BL-M11D1 administered Days 1, 4 7 or 8 in 28-day cycle
Cohort B: BL-M11D1 will be administered on Days 1,4, 7 or 8 by intravenous infusion every 28 days. |
The study includes 2 parts: Part 1 Dose escalation and Dose Finding |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Participants with dose-limiting toxicities
기간: 1 Year
|
DLTs are defined as any of the following events that are not clearly due to the underlying disease, disease progression, or extraneous causes:
|
1 Year
|
|
Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs)
기간: 1 Year
|
Measuring the number of patients with serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs) |
1 Year
|
|
To determine the minimum safe and effective dose (MSED), maximum tolerated dose (MTD) if reached, and maximum administered dose (MAD) of BL-M11D1 in AML
기간: 1 Year
|
Determine the highest BL-M11D1 dose level at which ≤33% subjects experience a DLT during the DLT evaluation period and highest BL-M11D1 dose administered in the event and MTD cannot be defined. |
1 Year
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cmax of BL-M11D1
기간: 1 Year
|
Calculate maximum (peak) observed concentration of BL-M11D1 |
1 Year
|
|
Tmax of BL-M11D1
기간: 1 Year
|
Calculate time of maximum observed concentration of BL-M1D1 |
1 Year
|
|
Tmax of free payload ED-04
기간: 1 Year
|
Calculate time of maximum observed concentration of free payload ED-04 |
1 Year
|
|
Cmax of free payload ED-04
기간: 1 Year
|
Calculate maximum (peak) observed concentration of free payload ED-04 |
1 Year
|
|
AUC(0-8) of BL-M11D1
기간: 1 Year
|
Calculate area under the serum concentration-time curve of BL-M11D1 from time 0 to 8 hours |
1 Year
|
|
AUC(0-8) of free payload ED-04
기간: 1 Year
|
Calculate area under the serum concentration-time curve of free payload ED-04 from time 0 to 8 hours |
1 Year
|
|
AUC(last) of BL-BM11D1
기간: 1 Year
|
Calculate area under the serum concentration-time curve up of BL-M11D1 to the last quantifiable time |
1 Year
|
|
AUC(last) of free payload ED-04
기간: 1 Year
|
Calculate area under the serum concentration-time curve up of free payload ED-04 to the last quantifiable time |
1 Year
|
|
Tmax of anti-CD33 antibody
기간: 1 Year
|
Calculate time of maximum observed concentration of anti-CD33 antibody |
1 Year
|
|
AUC (0-8) of anti-CD33 antibodies
기간: 1 Year
|
Calculate area under the serum concentration-time curve of anti-CD33 antibodies from time 0 to 8 hours |
1 Year
|
|
AUC (last) anti-CD33 antibodies
기간: 1 Year
|
Calculate area under the serum concentration-time curve up of anti-CD33 antibodies to the last quantifiable time |
1 Year
|
|
Overall Response Rate (ORR)
기간: 1 Year
|
To assess the clinical efficacy of BL-M11D1 as measured by ORR using RECIST criteria v 1.1 |
1 Year
|
|
Duration of response (DOR)
기간: 1 Year
|
To access the clinical efficacy of BL-M11D1 as measured by DOR using RECIST criteria 1.1 |
1 Year
|
|
Complete Remission (CR)
기간: 1 Year
|
To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria. |
1 Year
|
|
CR with partial hematologic recovery (CRh)
기간: 1 Year
|
To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria. |
1 Year
|
|
CR with incomplete hematologic recovery (CRi)
기간: 1 Year
|
To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria. |
1 Year
|
|
CR/CRi, CRs with or without measurable residual disease (MRD)
기간: 1 Year
|
To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria. |
1 Year
|
|
morphologic leukemia-free state (MLFS)
기간: 1 Year
|
To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria. |
1 Year
|
|
partial remission (PR)
기간: 1 Year
|
To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria. |
1 Year
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Olu Lawson, SystImmune Inc.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- BL-M11D1-HM-101
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .